Momenta Pharmaceuticals (MNTA) was Initiated by Aegis Capital to “Hold”. Aegis Capital advised their investors in a research report released on Nov 22, 2016.
Many Wall Street Analysts have commented on Momenta Pharmaceuticals. Company shares were Upgraded by Barclays on Oct 11, 2016 to ” Overweight”, Firm has raised the Price Target to $ 19 from a previous price target of $13 .Maxim Group Downgraded Momenta Pharmaceuticals on Sep 7, 2016 to ” Sell”, Price Target of the shares are set at $6.
On the company’s financial health, Momenta Pharmaceuticals reported $-0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $-0.30. The company had revenue of $299.14 million for the quarter, compared to analysts expectations of $25.68 million. The company’s revenue was up 2067.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.
Momenta Pharmaceuticals closed down -0.15 points or -1.09% at $13.55 with 7,46,203 shares getting traded on Monday. Post opening the session at $13.7, the shares hit an intraday low of $13.2 and an intraday high of $13.8 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Aug 23, 2016, Ganesh Venkataraman Kaundinya (Senior V.P., Research) sold 1,049 shares at $12.06 per share price. According to the SEC, on Aug 23, 2016, James M. Roach (Senior VP, Development and Chi) sold 1,091 shares at $12.06 per share price. On Aug 23, 2016, Bruce Leicher (SVP & General Counsel) sold 1,030 shares at $12.06 per share price, according to the Form-4 filing with the securities and exchange commission.
Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Companys product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.